[lyka_candelario]

I researched a few things about Vaxil Biotherapeutics and discovered that it was founded by Dr. Lior Carmon in 2006. Dr. Carmon is a biotechnology entrepreneur with a doctorate degree in immunology from Rehovot’s Weizmann Institute of Science. The company was then managed by a team of leading scientists and clinicians and is based in Weizmann Science Park, Nes-Ziona, Israel.

Knowing that Multiple Myeloma is malignant and by far, despite recent treatment advances, remains to be incurable. Ever since, it has become an everyday challenge for doctors and scientists to promise a cure.

There were several other clinical trials for Multiple Myeloma. One study, funded by the National Career Institute, which was started in July 1995, was coupled with chemotherapy where both were used as treatments for patients with such a condition. The vaccine was derived from a person’s tumor cells and allows the body to produce an immune response to kill its tumor cells. Its study design, like many others, was more of a treatment. The trial was completed on March 2007, with 60 patients in 3 treatment groups.

Another study, announced April of this year, known as the Specialized Program of Research Excellence (SPORE) is a collaboration of several research centers and universities. One of their projects is a vaccine therapy for Myeloma. Here the M-protein of a patient is isolated before treatment and eventually is used as a vaccine which makes the immune system destroy the myeloma’s cancer cells. Once the trial is successful together with a long time treatment (stem cell transplant), they will then conduct another trial where the vaccine is administered before the transplant.

Phase 2 of the study performed by the researchers from Beth Israel Deaconess Medical Center and Dana Farber Cancer Institute has recently shown promising results this May 2013. Its first clinical trial, the Phase 1, was submitted on April of 2010. Their research focused on fusing myeloma cancer cells to a patient’s dendritic cells. When the vaccine is given, that patient’s immune system is stimulated and destroys myeloma proteins. Their Phase 2 showed that immune responses of those vaccinated went more effective following an autologous stem cell transplant.

It is relieving to know that among many different trials, they all have a common goal, which is to lessen the unwanted effects of all therapies involved and increase survival rate.